

APM RESEARCH AND EVIDENCE-BASED PRACTICE COMMITTEE ESSENTIAL SCIENTIFIC PUBLICATIONS FOR PSYCHOSOMATIC MEDICINE

HIV PSYCHIATRY

PURPOSE:

Over the past decades, HIV Psychiatry has emerged as a small subspecialty within APM. While not all APM psychiatrists will routinely care for patients infected with HIV/AIDS, most can play some role in the HIV epidemic (e.g., in screening efforts). The Academy's Research and Evidence-based Practice Committee has coordinated a compilation of articles to identify essential scientific publications for members who are interested in learning more about critical issues in the care of patients infected with HIV/AIDS.

The purpose of the committee's review was to create a list of important publications in three categories, based on specific review criteria related to scientific quality and relevance. You will see three categories of articles:

Tier 1: Randomized controlled trials, meta-analyses, or high-impact review articles.

Tier 2: Comparison studies, non-randomized research of significance, highly relevant reviews.

Tier 3: Other articles of interest related to HIV Psychiatry not meeting inclusion criteria for Tier 1 or Tier 2.

Of note, this list is not a comprehensive list of all articles related to HIV Psychiatry but represents an attempt to identify a clinically useful selection of high-quality articles in this topic area. **Most recent articles from 2012 and 2013 are bolded and supplied with a PubMed link. No articles older than 2000 were included.**

METHOD:

A MEDLINE review of literature was conducted to identify articles in the scientific literature related to HIV Psychiatry. Search terms included HIV, psychiatry, treatment, randomized-controlled trial, depression, psychosis, dementia, HIV-associated neurocognitive impairment, adherence, mania, anxiety, substance use, and epidemiology. In addition, articles and book chapters were reviewed to identify articles that appeared to be useful. Two APM expert reviewers (Oliver Freudenreich and Maria Ferrara) independently categorized the articles according to specific rating criteria (tier 1, 2, and 3) and to specific categories of content (i.e., epidemiology, HIV-associated neurocognitive disorder (HAND), suicide, treatment (pharmacological and non-pharmacological), adherence, and other). Through an iterative process, consensus with regards to tier placement was achieved. Two other content matter experts (Mary Ann Cohen and Steven Safren) reviewed the bibliography list and made recommendations for additional articles to be included. Finally, the Research and Evidence-based Practice Committee reviewed the final list and approved it.

APM RESEARCH AND EVIDENCE-BASED PRACTICE COMMITTEE ESSENTIAL SCIENTIFIC PUBLICATIONS FOR PSYCHOSOMATIC MEDICINE

HIV PSYCHIATRY

Oliver Freudenreich, MD, FAPM

Maria Ferrara, MD

For the APM Research and Evidence-based Practice Committee*

A. EPIDEMIOLOGY

Tier 1

McDonnell MG, Srebnik D, Angelo F, McPherson S, Lowe JM, Sugar A, et al. Randomized controlled trial of contingency management for stimulant use in community mental health patients with serious mental illness. Am J Psychiatry. 2013;170(1):94-101.

<http://www.ncbi.nlm.nih.gov/pubmed/23138961>

Berkman A, Pilowsky DJ, Zybert PA, Herman DB, Conover S, Lemelle S, et al. HIV prevention with severely mentally ill men: a randomised controlled trial. *AIDS Care*. 2007;19(5):579-88.

Bing EG, Burnam MA, Longshore D, Fleishman JA, Sherbourne CD, London AS, et al. Psychiatric disorders and drug use among human immunodeficiency virus-infected adults in the United States. *Arch Gen Psychiatry*. 2001;58(8):721-8.

Tier 2

Machtiger EL, Wilson TC, Haberer JE, Weiss DS. Psychological trauma and PTSD in HIV-positive women: a meta-analysis. AIDS Behav. 2012;16(8):2091-100.

<http://www.ncbi.nlm.nih.gov/pubmed/22249954>

Meade CS. Sexual risk behavior among persons dually diagnosed with severe mental illness and substance use disorder. *J Subst Abuse Treat*. 2006;30(2):147-57.

Nakimuli-Mpungu E, Musisi S, Mpungu SK, Katabira E. Primary mania versus HIV-related secondary mania in Uganda. *Am J Psychiatry*. 2006;163(8):1349-54; quiz 480.

Carey MP, Carey KB, Maisto SA, Schroder KE, Vanable PA, Gordon CM. HIV risk behavior among psychiatric outpatients: association with psychiatric disorder, substance use disorder, and gender. *J Nerv Ment Dis*. 2004;192(4):289-96.

Burnam MA, Bing EG, Morton SC, Sherbourne C, Fleishman JA, London AS, et al. Use of mental health and substance abuse treatment services among adults with HIV in the United States. *Arch Gen Psychiatry*. 2001;58(8):729-36.

Rosenberg SD, Goodman LA, Osher FC, Swartz MS, Essock SM, Butterfield MI, et al. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. *Am J Public Health*. 2001;91(1):31-7.

Tier 3

Cohen, MA. How psychiatrists can prevent HIV transmission and provide compassionate care for persons with HIV and AIDS. Curr Psychiatry 2013 (in press).

Mitchell AJ, Lord O, Malone D. Differences in the prescribing of medication for physical disorders in individuals with v. without mental illness: meta-analysis. Br J Psychiatry. 2012;201(6):435-43.

<http://www.ncbi.nlm.nih.gov/pubmed/23209089>

Prince JD, Walkup J, Akincigil A, Amin S, Crystal S. Serious mental illness and risk of new HIV/AIDS diagnoses: an analysis of Medicaid beneficiaries in eight states. Psychiatr Serv. 2012;63(10):1032-8.

<http://www.ncbi.nlm.nih.gov/pubmed/22855268>

Wyatt GE, Williams JK, Gupta A, Malebranche D. Are cultural values and beliefs included in U.S. based HIV interventions? Prev Med. 2012;55(5):362-70.

<http://www.ncbi.nlm.nih.gov/pubmed/21884721>

Wu ES, Rothbard A, Blank MB. Using psychiatric symptomatology to assess risk for HIV infection in individuals with severe mental illness. Community Ment Health J. 2011;47(6):672-8.

Sikkema KJ, Watt MH, Drabkin AS, Meade CS, Hansen NB, Pence BW. Mental health treatment to reduce HIV transmission risk behavior: a positive prevention model. AIDS Behav. 2010;14(2):252-62.

Gaynes BN, Pence BW, Eron JJ, Jr., Miller WC. Prevalence and comorbidity of psychiatric diagnoses based on reference standard in an HIV+ patient population. Psychosom Med. 2008;70(4):505-11.

Meade CS, Graff FS, Griffin ML, Weiss RD. HIV risk behavior among patients with co-occurring bipolar and substance use disorders: associations with mania and drug abuse. Drug Alcohol Depend. 2008;92(1-3):296-300.

Leserman J, Pence BW, Whetten K, Mugavero MJ, Thielman NM, Swartz MS, et al. Relation of lifetime trauma and depressive symptoms to mortality in HIV. Am J Psychiatry. 2007;164(11):1707-13.

Marks G, Crepaz N, Senterfitt JW, Janssen RS. Meta-analysis of high-risk sexual behavior in persons aware and unaware they are infected with HIV in the United States: implications for HIV prevention programs. J Acquir Immune Defic Syndr. 2005;39(4):446-53.

Mills TC, Paul J, Stall R, Pollack L, Canchola J, Chang YJ, et al. Distress and depression in men who have sex with men: the Urban Men's Health Study. Am J Psychiatry. 2004;161(2):278-85.

Walkup JT, Sambamoorthi U, Crystal S. Use of newer antiretroviral treatments among HIV-infected medicaid beneficiaries with serious mental illness. J Clin Psychiatry. 2004;65(9):1180-9.

Rosenberg SD, Swanson JW, Wolford GL, Osher FC, Swartz MS, Essock SM, et al. The five-site health and risk study of blood-borne infections among persons with severe mental illness. Psychiatr Serv. 2003;54(6):827-35.

Stein MD, Solomon DA, Herman DS, Anderson BJ, Miller I. Depression severity and drug injection HIV risk behaviors. *Am J Psychiatry*. 2003;160(9):1659-62.

Vitiello B, Burnam MA, Bing EG, Beckman R, Shapiro MF. Use of psychotropic medications among HIV-infected patients in the United States. *Am J Psychiatry*. 2003;160(3):547-54.

Morrison MF, Petitto JM, Ten Have T, Gettes DR, Chiappini MS, Weber AL, et al. Depressive and anxiety disorders in women with HIV infection. *Am J Psychiatry*. 2002;159(5):789-96.

B. HIV-ASSOCIATED NEUROCOGNITIVE DISORDER (HAND)

Tier 1

The Mind Exchange Working Group. Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. *Clin Infect Dis*. 2013;56(7):1004-17.

<http://www.ncbi.nlm.nih.gov/pubmed/23175555>

Heaton RK, Franklin DR, Ellis RJ, McCutchan JA, Letendre SL, Leblanc S, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. *J Neurovirol*. 2011;17(1):3-16.

Heaton RK, Clifford DB, Franklin DR, Jr., Woods SP, Ake C, Vaida F, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. *Neurology*. 2010;75(23):2087-96.

Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neurocognitive disorders. *Neurology*. 2007;69(18):1789-99.

Tier 2

Crum-Cianflone NF, Moore DJ, Letendre S, Poehlman RM, Eberly L, Weintrob A, et al. Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. *Neurology*. 2013;80(4):371-379.

<http://www.ncbi.nlm.nih.gov/pubmed/23303852>

Blackstone K, Moore DJ, Franklin DR, Clifford DB, Collier AC, Marra CM, et al. Defining neurocognitive impairment in HIV: deficit scores versus clinical ratings. *Clin Neuropsychol*. 2012;26(6):894-908.

<http://www.ncbi.nlm.nih.gov/pubmed/22708483>

Ellis RJ, Badiee J, Vaida F, Letendre S, Heaton RK, Clifford D, et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. *Aids*. 2011;25(14):1747-51.

Letendre S. Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. *Top Antivir Med*. 2011;19(4):137-42.

Schouten J, Cinque P, Gisslen M, Reiss P, Portegies P. HIV-1 infection and cognitive impairment in the cART era: a review. *Aids*. 2011;25(5):561-75.

Spudich S, Gisslen M, Hagberg L, Lee E, Liegler T, Brew B, et al. Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants

with minimal cerebrospinal fluid viral burden. *J Infect Dis.* 2011;204(5):753-60.

Applebaum AJ, Otto MW, Richardson MA, Safren SA. Contributors to neuropsychological impairment in HIV-infected and HIV-uninfected opiate-dependent patients. *J Clin Exp Neuropsychol.* 2010;32(6):579-89.

Letendre SL, Ellis RJ, Ances BM, McCutchan JA. Neurologic complications of HIV disease and their treatment. *Top HIV Med.* 2010;18(2):45-55.

Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. *Aids.* 2010;24(9):1243-50.

Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. *Arch Neurol.* 2008;65(1):65-70.

Cysique LA, Brew BJ, Halman M, Catalan J, Sacktor N, Price RW, et al. Undetectable cerebrospinal fluid HIV RNA and beta-2 microglobulin do not indicate inactive AIDS dementia complex in highly active antiretroviral therapy-treated patients. *J Acquir Immune Defic Syndr.* 2005;39(4):426-9.

Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. *J Neurovirol.* 2004;10(6):350-7.

Dore GJ, McDonald A, Li Y, Kaldor JM, Brew BJ. Marked improvement in survival following AIDS dementia complex in the era of highly active antiretroviral therapy. *Aids.* 2003;17(10):1539-45.

Tier 3

Kumar AM, Ownby RL, Waldrop-Valverde D, Fernandez B, Kumar M. Human immunodeficiency virus infection in the CNS and decreased dopamine availability: relationship with neuropsychological performance. *J Neurovirol.* 2011;17(1):26-40.

Cysique LA, Vaida F, Letendre S, Gibson S, Cherner M, Woods SP, et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. *Neurology.* 2009;73(5):342-8.

Ances BM, Ellis RJ. Dementia and neurocognitive disorders due to HIV-1 infection. *Semin Neurol.* 2007;27(1):86-92.

Green JE, Saveanu RV, Bornstein RA. The effect of previous alcohol abuse on cognitive function in HIV infection. *Am J Psychiatry.* 2004;161(2):249-54.

Jernigan TL, Gamst AC, Archibald SL, Fennema-Notestine C, Mindt MR, Marcotte TD, et al. Effects of methamphetamine dependence and HIV infection on cerebral morphology. *Am J Psychiatry.* 2005;162(8):1461-72.

C. SUICIDE

Tier 1

None

Tier 2

Keiser O, Spoerri A, Brinkhof MW, Hasse B, Gayet-Ageron A, Tissot F, et al. Suicide in HIV-infected individuals and the general population in Switzerland, 1988-2008. *Am J Psychiatry*. 2010;167(2):143-50.

Tier 3

Catalan J, Harding R, Sibley E, Clucas C, Croome N, Sherr L. HIV infection and mental health: suicidal behaviour--systematic review. *Psychol Health Med*. 2011;16(5):588-611.

D. TREATMENT – PHARMACOLOGICAL INTERVENTIONS

Tier 1

Epidemiology

Lee S, Rothbard AB, Noll E, Blank MB. Use of HIV and psychotropic medications among persons with serious mental illness and HIV/AIDS. *Adm Policy Ment Health*. 2011;38(5):335-44.

Depression and fatigue

Rabkin JG, McElhiney MC, Rabkin R. Treatment of HIV-related fatigue with armodafinil: a placebo-controlled randomized trial. *Psychosomatics*. 2011;52(4):328-36.

Rabkin JG, McElhiney MC, Rabkin R, McGrath PJ. Modafinil treatment for fatigue in HIV/AIDS: a randomized placebo-controlled study. *J Clin Psychiatry*. 2010;71(6):707-15.

Rabkin JG, McElhiney MC, Rabkin R, McGrath PJ, Ferrando SJ. Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS. *Am J Psychiatry*. 2006;163(1):59-66.

Rabkin JG, Wagner GJ, McElhiney MC, Rabkin R, Lin SH. Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. *J Clin Psychopharmacol*. 2004;24(4):379-85.

Breitbart W, Rosenfeld B, Kaim M, Funesti-Esch J. A randomized, double-blind, placebo-controlled trial of psychostimulants for the treatment of fatigue in ambulatory patients with human immunodeficiency virus disease. *Arch Intern Med*. 2001;161(3):411-20.

Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. *Arch Gen Psychiatry*. 2000;57(2):141-7; discussion 55-6.

Painful HIV neuropathy

Simpson DM, Schifitto G, Clifford DB, Murphy TK, Durso-De Cruz E, Glue P, et al. Pregabalin for painful HIV neuropathy: a randomized, double-blind, placebo-controlled trial. *Neurology*. 2010;74(5):413-20.

Simpson DM, McArthur JC, Olney R, Clifford D, So Y, Ross D, et al. Lamotrigine for HIV-associated painful sensory neuropathies: a placebo-controlled trial. *Neurology*. 2003;60(9):1508-14.

Tier 2

Hahn K, Arendt G, Braun JS, von Giesen HJ, Husstedt IW, Maschke M, et al. A placebo-controlled trial of gabapentin for painful HIV-associated sensory neuropathies. *J Neurol*. 2004;251(10):1260-6.

Wagner GJ, Rabkin R. Effects of dextroamphetamine on depression and fatigue in men with HIV: a double-blind, placebo-controlled trial. *J Clin Psychiatry*. 2000;61(6):436-40.

Tier 3

Hill L, Lee KC. Pharmacotherapy considerations in patients with HIV and psychiatric disorders: focus on antidepressants and antipsychotics. *Ann Pharmacother*. 2013;47(1):75-89.
<http://www.ncbi.nlm.nih.gov/pubmed/23341158>

Gallego L, Barreiro P, Lopez-Ibor JJ. Psychopharmacological treatments in HIV patients under antiretroviral therapy. *AIDS Rev*. 2012;14(2):101-11.
<http://www.ncbi.nlm.nih.gov/pubmed/22627606>

Watkins CC, Pieper AA, Treisman GJ. Safety considerations in drug treatment of depression in HIV-positive patients: an updated review. *Drug Saf*. 2011;34(8):623-39.

Ferrando SJ, Freyberg Z. Treatment of depression in HIV positive individuals: a critical review. *Int Rev Psychiatry*. 2008;20(1):61-71.

Rabkin JG. HIV and depression: 2008 review and update. *Curr HIV/AIDS Rep*. 2008;5(4):163-71.

Repetto MJ, Petitto JM. Psychopharmacology in HIV-infected patients. *Psychosom Med*. 2008;70(5):585-92.

Singh D, Goodkin K. Psychopharmacologic treatment response of HIV-infected patients to antipsychotic medications. *The Journal of clinical psychiatry*. 2007;68(4):631-2.
J Clin Psychiatry. 2007 Apr;68(4):631-2.

Olatunji BO, Mimiaga MJ, O'Cleirigh C, Safren SA. Review of treatment studies of depression in HIV. *Top HIV Med*. 2006;14(3):112-24.

Himelhoch S, Medoff DR. Efficacy of antidepressant medication among HIV-positive individuals with depression: a systematic review and meta-analysis. *AIDS Patient Care STDS*. 2005;19(12):813-22.

Drug-interactions

Wynn GH, Cozza KL, Zapor MJ, Wortmann GW, Armstrong SC. Med-psych drug-drug interactions update. Antiretrovirals, part III: antiretrovirals and drugs of abuse. *Psychosomatics*. 2005;46(1):79-87.

Zapor MJ, Cozza KL, Wynn GH, Wortmann GW, Armstrong SC. Antiretrovirals, Part II: focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors). *Psychosomatics*. 2004;45(6):524-35.

Wynn GH, Zapor MJ, Smith BH, Wortmann G, Oesterheld JR, Armstrong SC, et al. Antiretrovirals, part 1: overview, history, and focus on protease inhibitors. *Psychosomatics*. 2004;45(3):262-70.

E. TREATMENT – NONPHARMACOLOGICAL INTERVENTIONS

Tier 1

Safren SA, O'Cleirigh CM, Skeer M, Elsesser SA, Mayer KH. Project enhance: a randomized controlled trial of an individualized HIV prevention intervention for HIV-infected men who have sex with men conducted in a primary care setting. Health Psychol. 2013;32(2):171-9.

<http://www.ncbi.nlm.nih.gov/pubmed/22746262>

Safren SA, O'Cleirigh CM, Bullis JR, Otto MW, Stein MD, Pollack MH. Cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected injection drug users: a randomized controlled trial. J Consult Clin Psychol. 2012;80(3):404-15.

<http://www.ncbi.nlm.nih.gov/pubmed/22545737>

Duncan LG, Moskowitz JT, Neilands TB, Dilworth SE, Hecht FM, Johnson MO. Mindfulness-based stress reduction for HIV treatment side effects: a randomized, wait-list controlled trial. J Pain Symptom Manage. 2012;43(2):161-71.

<http://www.ncbi.nlm.nih.gov/pubmed/21925831>

Kalichman SC, Cherry C, Kalichman MO, Amaral CM, White D, Pope H, et al. Integrated behavioral intervention to improve HIV/AIDS treatment adherence and reduce HIV transmission. Am J Public Health. 2011;101(3):531-8.

Sherr L, Clucas C, Harding R, Sibley E, Catalan J. HIV and depression--a systematic review of interventions. Psychol Health Med. 2011;16(5):493-527.

Safren SA, O'Cleirigh C, Tan JY, Raminani SR, Reilly LC, Otto MW, et al. A randomized controlled trial of cognitive behavioral therapy for adherence and depression (CBT-AD) in HIV-infected individuals. Health Psychol. 2009;28(1):1-10.

The Healthy Living Project. Effects of a behavioral intervention to reduce risk of transmission among people living with HIV: the healthy living project randomized controlled study. J Acquir Immune Defic Syndr. 2007;44(2):213-21.

Himelhoch S, Medoff DR, Oyenyi G. Efficacy of group psychotherapy to reduce depressive symptoms among HIV-infected individuals: a systematic review and meta-analysis. AIDS Patient Care STDS. 2007;21(10):732-9.

Chesney MA, Chambers DB, Taylor JM, Johnson LM, Folkman S. Coping effectiveness training for men living with HIV: results from a randomized clinical trial testing a group-based intervention. Psychosom Med. 2003;65(6):1038-46.

Tier 2

Antoni MH, Cruess S, Cruess DG, Kumar M, Lutgendorf S, Ironson G, et al. Cognitive-behavioral stress management reduces distress and 24-hour urinary free cortisol output among symptomatic HIV-infected gay men. Ann Behav Med. 2000;22(1):29-37.

Cruess DG, Antoni MH, Schneiderman N, Ironson G, McCabe P, Fernandez JB, et al. Cognitive-behavioral stress management increases free testosterone and decreases psychological distress in HIV-seropositive men. Health Psychol. 2000;19(1):12-20.

Tier 3

Olatunji BO, Mimiaga MJ, O'Cleirigh C, Safren SA. Review of treatment studies of depression in HIV. *Top HIV Med.* 2006;14(3):112-24.

F. ADHERENCE

Tier 1

Tsai AC, Karasic DH, Hammer GP, Charlebois ED, Ragland K, Moss AR, et al. Directly observed antidepressant medication treatment and HIV outcomes among homeless and marginally housed HIV-positive adults: a randomized controlled trial. *Am J Public Health.* 2013;103(2):308-15.

<http://www.ncbi.nlm.nih.gov/pubmed/22720766>

Gonzalez JS, Batchelder AW, Psaros C, Safren SA. Depression and HIV/AIDS treatment nonadherence: a review and meta-analysis. *J Acquir Immune Defic Syndr.* 2011;58(2):181-7.

Malta M, Strathdee SA, Magnanini MM, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. *Addiction.* 2008;103(8):1242-57.

Tier 2

Badiee J, Riggs PK, Rooney AS, Vaida F, Grant I, Atkinson JH, et al. Approaches to identifying appropriate medication adherence assessments for HIV infected individuals with comorbid bipolar disorder. *AIDS Patient Care STDS.* 2012;26(7):388-394.

<http://www.ncbi.nlm.nih.gov/pubmed/22686169>

Mayston R, Kinyanda E, Chishinga N, Prince M, Patel V. Mental disorder and the outcome of HIV/AIDS in low-income and middle-income countries: a systematic review. *Aids.* 2012;26 Suppl 2:S117-35.

<http://www.ncbi.nlm.nih.gov/pubmed/23303434>

Milloy MJ, Kerr T, Bangsberg DR, Buxton J, Parashar S, Guillemi S, et al. Homelessness as a structural barrier to effective antiretroviral therapy among HIV-seropositive illicit drug users in a Canadian setting. *AIDS Patient Care STDS.* 2012;26(1):60-7.

<http://www.ncbi.nlm.nih.gov/pubmed/22107040>

Tsai AC, Weiser SD, Petersen ML, Ragland K, Kushel MB, Bangsberg DR. A marginal structural model to estimate the causal effect of antidepressant medication treatment on viral suppression among homeless and marginally housed persons with HIV. *Arch Gen Psychiatry.* 2010;67(12):1282-90.

Tier 3

Blackstone K, Woods SP, Weber E, Grant I, Moore, DJ; HNRG Group. Memory-based strategies for antiretroviral medication management: an evaluation of clinical predictors, adherence behavior awareness, and effectiveness. *AIDS Behav.* 2013;17(1):74-85.

<http://www.ncbi.nlm.nih.gov/pubmed/22968399>

Moore DJ, Posada C, Parikh M, Arce M, Vaida F, Riggs PK, et al. HIV-infected individuals with co-occurring bipolar disorder evidence poor antiretroviral and psychiatric medication adherence. *AIDS Behav.* 2012;16(8):2257-2266.

<http://www.ncbi.nlm.nih.gov/pubmed/22041931>

G. OTHER

Efavirenz

Tier 1

Dabaghzadeh F, Ghaeli P, Khalili H, Alimadadi A, Jafari S, Akhondzadeh S, et al. Cyproheptadine for prevention of neuropsychiatric adverse effects of efavirenz: a randomized clinical trial. AIDS Patient Care STDS. 2013;27(3):146-54.
<http://www.ncbi.nlm.nih.gov/pubmed/23442031>

Read TR, Carey D, Mallon P, Mijch A, Goodall R, Hudson F, et al. Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial. *Aids*. 2009;23(16):2222-3.

Gutierrez-Valencia A, Viciano P, Palacios R, Ruiz-Valderas R, Lozano F, Terron A, et al. Stepped-dose versus full-dose efavirenz for HIV infection and neuropsychiatric adverse events: a randomized trial. *Ann Intern Med*. 2009;151(3):149-56.

Tier 2

Kenedi CA, Goforth HW. A systematic review of the psychiatric side-effects of efavirenz. *AIDS Behav*. 2011;15(8):1803-18.

Screening

Tier 2

Sanger C, Hayward J, Patel G, Phekoo K, Poots AJ, Howe C, et al. Acceptability and necessity of HIV and other blood-borne virus testing in a psychiatric setting. Br J Psychiatry. 2013;202(4):307-8.
<http://www.ncbi.nlm.nih.gov/pubmed/23549943>

Senn TE, Carey MP. HIV testing among individuals with a severe mental illness: review, suggestions for research, and clinical implications. *Psychol Med*. 2009;39(3):355-63.

Meade CS, Sikkema KJ. Voluntary HIV testing among adults with severe mental illness: frequency and associated factors. *AIDS Behav*. 2005;9(4):465-73.

Walkup J, Satriano J, Barry D, Sadler P, Cournos F. HIV testing policy and serious mental illness. *Am J Public Health*. 2002;92(12):1931-40.

Education

Tier 3

Cohen MA, Forstein M. A biopsychosocial approach to HIV/AIDS education for psychiatry residents. Acad Psychiatry. 2012;36(6):479-86.
<http://www.ncbi.nlm.nih.gov/pubmed/23154699>

Smoking

Tier 2

Lifson AR, Lando HA. Smoking and HIV: prevalence, health risks, and cessation strategies. Curr HIV/AIDS Rep. 2012;9(3):223-30.
<http://www.ncbi.nlm.nih.gov/pubmed/22618079>

Valproic acid

Tier 3

Routy JP, Tremblay CL, Angel JB, Trottier B, Rouleau D, Baril JG, et al. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med. 2012;13(5):291-6.
<http://www.ncbi.nlm.nih.gov/pubmed/22276680>

ADDENDUM

Books about HIV Psychiatry

Handbook of AIDS psychiatry by Mary Ann Cohen, Harold Goforth, Joseph Lux, et al. Oxford University Press, 2010.

Comprehensive textbook of AIDS psychiatry by Mary Ann Cohen and Jack M. Gorman (editors). Oxford University Press, 2008.

Psychiatric aspects of HIV/AIDS by Francisco Fernandez and Pedro Ruiz (editors). Lippincott Williams & Wilkins, 2006.

The psychiatry of AIDS: a guide to diagnosis and treatment by Glen J. Treisman and Andrew F. Angelino. The Johns Hopkins University Press, 2004.

HIV Clinical Guidelines

New York State Department of Health AIDS Institute in collaboration with Johns Hopkins University Division of Infectious Diseases:
<http://www.hivguidelines.org/>

***Acknowledgments:**

APM Clinical Practice and Research Committee:

Michael Sharpe, MD, FAPM

Robert Boland, MD, FAPM

Oliver Freudenreich, MD, FAPM

Jeff Huffman, MD, FAPM

We would like to thank Mary Ann Cohen, MD, FAPM and Steven Safren, PhD for independently reviewing the tiered list and making recommendations for additional papers.